US20070148151A1 - Processes for the manufacture and use of pancreatin - Google Patents

Processes for the manufacture and use of pancreatin Download PDF

Info

Publication number
US20070148151A1
US20070148151A1 US11/460,330 US46033006A US2007148151A1 US 20070148151 A1 US20070148151 A1 US 20070148151A1 US 46033006 A US46033006 A US 46033006A US 2007148151 A1 US2007148151 A1 US 2007148151A1
Authority
US
United States
Prior art keywords
pancreatin
heating
solvents
hours
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/460,330
Other languages
English (en)
Inventor
Martin Frink
Claus-Juergen Koelln
Heinz Blume
Michael Rust
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070148151(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Priority to US11/460,330 priority Critical patent/US20070148151A1/en
Assigned to SOLVAY PHARMACEUTICALS GMBH reassignment SOLVAY PHARMACEUTICALS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FRINK, MARTIN, BLUME, HEINZ, RUST, MICHAEL, KOELLN, CLAUS-JUERGEN
Publication of US20070148151A1 publication Critical patent/US20070148151A1/en
Assigned to ABBOTT PRODUCTS GMBH reassignment ABBOTT PRODUCTS GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SOLVAY PHARMACEUTICALS GMBH
Priority to US15/214,973 priority patent/US10704037B2/en
Priority to US16/893,036 priority patent/US20200299669A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US11/460,330 2005-07-29 2006-07-27 Processes for the manufacture and use of pancreatin Abandoned US20070148151A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/460,330 US20070148151A1 (en) 2005-07-29 2006-07-27 Processes for the manufacture and use of pancreatin
US15/214,973 US10704037B2 (en) 2005-07-29 2016-07-20 Processes for the manufacture and use of pancreatin
US16/893,036 US20200299669A1 (en) 2005-07-29 2020-06-04 Processes for the Manufacture and Use of Pancreatin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70381305P 2005-07-29 2005-07-29
EP05016533 2005-07-29
US11/460,330 US20070148151A1 (en) 2005-07-29 2006-07-27 Processes for the manufacture and use of pancreatin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/214,973 Continuation US10704037B2 (en) 2005-07-29 2016-07-20 Processes for the manufacture and use of pancreatin

Publications (1)

Publication Number Publication Date
US20070148151A1 true US20070148151A1 (en) 2007-06-28

Family

ID=35457614

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/460,330 Abandoned US20070148151A1 (en) 2005-07-29 2006-07-27 Processes for the manufacture and use of pancreatin
US15/214,973 Active US10704037B2 (en) 2005-07-29 2016-07-20 Processes for the manufacture and use of pancreatin
US16/893,036 Abandoned US20200299669A1 (en) 2005-07-29 2020-06-04 Processes for the Manufacture and Use of Pancreatin

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/214,973 Active US10704037B2 (en) 2005-07-29 2016-07-20 Processes for the manufacture and use of pancreatin
US16/893,036 Abandoned US20200299669A1 (en) 2005-07-29 2020-06-04 Processes for the Manufacture and Use of Pancreatin

Country Status (18)

Country Link
US (3) US20070148151A1 (pt)
EP (2) EP2278002B1 (pt)
JP (1) JP5140586B2 (pt)
KR (1) KR101555058B1 (pt)
CN (1) CN101233229B (pt)
AU (1) AU2006274835B2 (pt)
BR (1) BRPI0614914A2 (pt)
CA (1) CA2616943C (pt)
ES (2) ES2635308T3 (pt)
HK (1) HK1120288A1 (pt)
HU (2) HUE031042T2 (pt)
IL (1) IL189103A (pt)
MX (1) MX2008000850A (pt)
NO (2) NO340996B1 (pt)
PL (2) PL2278002T3 (pt)
RU (1) RU2413532C2 (pt)
UA (1) UA93384C2 (pt)
WO (1) WO2007014896A1 (pt)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071683A1 (en) * 1999-12-17 2004-04-15 Fallon Joan M. Methods for treating pervasive development disorders
US20050250817A1 (en) * 2004-03-22 2005-11-10 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20070148153A1 (en) * 2005-08-15 2007-06-28 George Shlieout Controlled release pharmaceutical compositions for acid-labile drugs
US20070148152A1 (en) * 2005-08-15 2007-06-28 George Shlieout Process for the manufacture and use of pancreatin micropellet cores
US20070270976A1 (en) * 2002-04-25 2007-11-22 Ultraflex Systems, Inc. Ambulating ankle & knee joints with bidirectional dampening and assistance using elastomeric restraint
US20080019959A1 (en) * 2006-05-22 2008-01-24 Dietmar Becher Process for separating and determining the viral load in a pancreatin sample
US20080152637A1 (en) * 2000-08-14 2008-06-26 Fallon Joan M Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders
US20080166334A1 (en) * 2004-09-28 2008-07-10 Fallon Joan M Combination enzyme for cystic fibrosis
DE202008014562U1 (de) 2008-11-03 2009-02-26 Nordmark Arzneimittel Gmbh & Co. Kg Pankreatin
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090226414A1 (en) * 2008-03-07 2009-09-10 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US20090233344A1 (en) * 2008-03-11 2009-09-17 Nordmark Arzneimittel Gmbh & Co. Kg Pancreatin and method for reducing the viral and microbial contamination of pancreatin
US20090232789A1 (en) * 2008-03-13 2009-09-17 Fallon Joan M Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy
US20090324572A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of williams syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
US20100169409A1 (en) * 2008-08-04 2010-07-01 Fallon Joan M Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain
US20100260857A1 (en) * 2009-04-13 2010-10-14 Joan Fallon Enzyme delivery systems and methods of preparation and use
WO2011035079A1 (en) 2009-09-17 2011-03-24 Eurand, Inc. Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US20110182818A1 (en) * 2008-07-01 2011-07-28 Fallon Joan M Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US8318158B2 (en) 2008-04-18 2012-11-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9259393B2 (en) 2000-11-15 2016-02-16 Aptalis Pharma S.R.L. Microspheres of pancreatic enzymes with high stability and production method thereof
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US9976171B2 (en) 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
US10206882B2 (en) 2007-02-20 2019-02-19 Allergan Pharmaceuticals International Limited Stable digestive enzyme compositions
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
US11364205B2 (en) 2010-10-01 2022-06-21 Societe Des Produits Nestle S.A. Stable low digestive enzyme content formulation
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014896A1 (en) 2005-07-29 2007-02-08 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
WO2009063065A1 (en) * 2007-11-15 2009-05-22 Solvay Pharmaceuticals Gmbh Novel process for separating and determining the viral load in a pancreatin sample
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
CN102884181A (zh) * 2010-03-19 2013-01-16 加拿大阿普塔利斯制药公司 用于药用胰腺酶制剂中的病毒灭活的β-丙内酯
JP5814094B2 (ja) * 2011-11-30 2015-11-17 ふたみ青果株式会社 遠赤外線ヒーターによる凍結乾燥方法とその装置
ES2834483T3 (es) 2013-11-05 2021-06-17 Allergan Pharmaceuticals Int Ltd Composiciones farmacéuticas de pancreatina de alta potencia
EP3215181A1 (en) * 2014-11-05 2017-09-13 Abbott Laboratories GmbH Processes for producing compositions with improved safety profile comprising pancreatin and compositions suitable for pharmaceutical use
WO2016187455A1 (en) 2015-05-19 2016-11-24 Scientific Protein Laboratories, Llc Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin
DE102015119006A1 (de) 2015-11-05 2017-05-11 Nordmark Arzneimittel Gmbh & Co. Kg Verfahren zur Reduzierung der Belastung von Pankreatin mit Mikroorganismen
PT3436055T (pt) 2016-03-28 2024-01-29 Abbott Laboratories Gmbh Composições enzimáticas com uma reduzida contaminação viral e microbiana
US11278603B2 (en) 2016-03-28 2022-03-22 Abbvie Inc. Enzyme compositions with reduced viral and microbial contamination
KR101813920B1 (ko) * 2016-07-06 2018-01-04 넨시스(주) 판크레아틴의 살균방법 및 이를 이용한 판크레아틴 제조방법
WO2019067743A1 (en) 2017-09-27 2019-04-04 Abbvie Inc. ENZYME COMPOSITIONS HAVING MICROBIAL CONTAMINATION AND REDUCED VIRAL

Citations (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324002A (en) * 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
US3803305A (en) * 1962-12-28 1974-04-09 Rolland A Lab Process for obtaining extracts from pancreas
US3950508A (en) * 1972-05-10 1976-04-13 Laboratoires Servier Process for obtaining pharmaceutical sustained releases
US3956483A (en) * 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
US3986927A (en) * 1975-04-28 1976-10-19 Armour Pharmaceutical Company Process for the purification and sterilization of acidophilic biologicals by extreme acidification at cold temperatures
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
US4019958A (en) * 1975-03-22 1977-04-26 Kali-Chemie Pharma Gmbh Continuous process of producing pancreatin and product thereof
US4079125A (en) * 1975-06-10 1978-03-14 Johnson & Johnson Preparation of enteric coated digestive enzyme compositions
US4106991A (en) * 1976-07-07 1978-08-15 Novo Industri A/S Enzyme granulate composition and process for forming enzyme granulates
US4280971A (en) * 1979-06-08 1981-07-28 Kali-Chemie Pharma Gmbh Process for the production of pancreatin pellets
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
US4533562A (en) * 1981-04-13 1985-08-06 Sankyo Company, Limited Method of preparing coated solid preparations
US4623624A (en) * 1982-12-30 1986-11-18 Basf Aktiengesellschaft Isolation of pancreatin
US4689297A (en) * 1985-03-05 1987-08-25 Miles Laboratories, Inc. Dust free particulate enzyme formulation
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4786505A (en) * 1986-04-30 1988-11-22 Aktiebolaget Hassle Pharmaceutical preparation for oral use
US4929774A (en) * 1988-01-29 1990-05-29 Basf Aktiengesellschaft Stable mixture containing oxidation-sensitive compounds, preparation thereof and use of a combination of substances for stabilizing oxidation-sensitive compounds
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5300433A (en) * 1989-06-15 1994-04-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5324649A (en) * 1991-10-07 1994-06-28 Genencor International, Inc. Enzyme-containing granules coated with hydrolyzed polyvinyl alcohol or copolymer thereof
US5374657A (en) * 1991-01-24 1994-12-20 Martek Corporation Microbial oil mixtures and uses thereof
US5378462A (en) * 1992-08-19 1995-01-03 Kali-Chemie Pharma Gmbh Pancreatin micropellets prepared with polyethylene glycol 4000, paraffin and a lower alcohol by extrusion and rounding
US5489530A (en) * 1991-07-01 1996-02-06 Basf Aktiengesellschaft Lipase from Pseudomonas and strain
US5536661A (en) * 1987-03-10 1996-07-16 Novo Nordisk A/S Process for the production of protein products in aspergillus
US5570104A (en) * 1993-02-24 1996-10-29 Sony Corporation Discharge chamber and method of manufacturing the same
US5614189A (en) * 1990-06-06 1997-03-25 Novo Nordisk A/S Recombinantly produced lipases for therapeutical treatment
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US5658871A (en) * 1989-07-07 1997-08-19 Lever Brothers Company, Division Of Conopco, Inc. Microbial lipase muteins and detergent compositions comprising same
US5719115A (en) * 1993-07-05 1998-02-17 Henkel Kommanditgesellschaft Auf Aktien Coated enzyme preparation for detergents and cleaning formulations
US5725880A (en) * 1994-03-11 1998-03-10 Tanabe Seiyaku Co., Ltd. Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract
US5750148A (en) * 1994-08-19 1998-05-12 Shin-Etsu Chemical Co., Ltd. Method for preparing solid enteric pharmaceutical preparation
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5766912A (en) * 1986-03-17 1998-06-16 Novo Nordisk A/S Humicola lipase produced in aspergillus
US5783545A (en) * 1993-12-23 1998-07-21 Henkel Kommanditgesellschaft Auf Aktien Enzyme preparation containing a silver corrosion inhibitor
US5801022A (en) * 1990-08-03 1998-09-01 Vertex Pharmaceuticals, Incorporated Method of producing a product with crosslinked crystals of thermolysin
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
US5874558A (en) * 1986-03-17 1999-02-23 Novo Nordisk Nucleic acid encoding a recombinant humicola sp. lipase
US5879920A (en) * 1991-10-07 1999-03-09 Genencor International, Inc. Coated enzyme-containing granule
US5993806A (en) * 1996-08-28 1999-11-30 Solvay Pharmaceuticals Gmbh Method of stabilizing pharmaceutical preparations comprising digestive enzyme mixtures
US6025391A (en) * 1996-04-12 2000-02-15 Novartis Ag Enteric-coated pharmaceutical compositions of mycophenolate
US6051220A (en) * 1995-05-31 2000-04-18 Medzyme N.V. And Simon Lodewijk Scharpe Composition to improve digestibility and utilization of nutrients
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US6187572B1 (en) * 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US6224910B1 (en) * 1998-05-22 2001-05-01 Bristol-Myers Squibb Company Method for the preparation of an enteric coated high drug load pharmaceutical composition
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6278794B1 (en) * 1996-11-29 2001-08-21 Oxford Glycosciences (Uk) Ltd Computer-assisted isolation and characterization of proteins
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US6348442B2 (en) * 1998-06-30 2002-02-19 Novozymes A/S Enzyme containing granule
US6355461B2 (en) * 1996-04-29 2002-03-12 Novozymes A/S Non-aqueous, liquid, enzyme-containing compositions
US20020061302A1 (en) * 1999-03-17 2002-05-23 Suntje Sander-Struckmeier Method for the treatment of diabetes
US20020076438A1 (en) * 1998-05-22 2002-06-20 Ismat Ullah High drug load acid labile pharmaceutical composition
US6426091B1 (en) * 1997-09-30 2002-07-30 Nikken Chemicals Co., Ltd. Sustained-release theophylline tablet
US20020146451A1 (en) * 2000-07-15 2002-10-10 Sharma Virender K. Method for the administration of acid-labile drugs
US20030007962A1 (en) * 2001-05-23 2003-01-09 Vergez Juan A. Pharmaceutical composition containing mosapride and pancreatin
US20030049245A1 (en) * 2001-08-31 2003-03-13 Mann David M. Methods for sterilizing preparations of digestive enzymes
US20030086948A1 (en) * 2001-07-27 2003-05-08 Gattefosse S.A. Pharmaceutical composition for oral use comprising an active principle to undergo a large first intestinal passage effect
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US20030175259A1 (en) * 1998-03-09 2003-09-18 Hamper Karageozian Use of corneal hardening agents in enzymeorthokeratology
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040013697A1 (en) * 2000-05-30 2004-01-22 Gunther Berndl Self-emulsifying active substance formulation and use of this formulation
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US20040033220A1 (en) * 2000-11-02 2004-02-19 Marcus Hartmann Use of enzymes obtained from ciliates as medicaments for promoting digestion
US20040057944A1 (en) * 2001-01-19 2004-03-25 Solvay Pharmaceuticals Gmbh Microbial enzyme mixtures useful to treat digestive disorders
US6734188B1 (en) * 1999-11-01 2004-05-11 John Rhodes Composition for treatment of constipation and irritable bowel syndrome
US20040101562A1 (en) * 2000-11-15 2004-05-27 Mario Maio Microspheres of pancreatic enzymes with high stability and production method thereof
US6767729B1 (en) * 1999-05-27 2004-07-27 Amano Enzyme Inc. Enzyme liquor and process for producing the same enzyme preparation protease preparations and protease-producing bacterium
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
US20050250817A1 (en) * 2004-03-22 2005-11-10 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US7211281B2 (en) * 1999-12-30 2007-05-01 Kemin Industries, Inc. Method for improving the activity of enzymes
US20070148153A1 (en) * 2005-08-15 2007-06-28 George Shlieout Controlled release pharmaceutical compositions for acid-labile drugs
US20070148152A1 (en) * 2005-08-15 2007-06-28 George Shlieout Process for the manufacture and use of pancreatin micropellet cores
US20080019959A1 (en) * 2006-05-22 2008-01-24 Dietmar Becher Process for separating and determining the viral load in a pancreatin sample
US7479378B2 (en) * 2003-07-29 2009-01-20 Solvay Pharmaceuticals Gmbh Method of analyzing enzyme compositions with lipolytic, proteolytic and amylolytic activity
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090226414A1 (en) * 2008-03-07 2009-09-10 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2189948A (en) 1938-10-31 1940-02-13 Griffith Laboratories Sterilization of pancreatin
US2503313A (en) 1947-04-14 1950-04-11 Levin Ezra Production of dried, defatted enzymatic material
DE2035739A1 (en) 1970-07-18 1972-01-27 Röhm FmbH, 6100 Darmstadt Oral enzyme prepsn - consisting of granulate with gastric juices-resistant coating in tablet or capsule form
JPS4936886A (pt) * 1972-08-15 1974-04-05
JPS5543723B2 (pt) 1972-08-24 1980-11-07
DE2410241A1 (de) 1974-03-04 1975-09-18 Christian Brunnengraeber Chem Granulataehnliche darreichungsform fuer arzneimittel
GB1603640A (en) 1977-07-20 1981-11-25 Gist Brocades Nv Enzyme particles
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4259440A (en) 1979-05-21 1981-03-31 Miles Laboratories, Inc. Hydrolysis and assay of triglycerides
JPS5855125B2 (ja) 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
JPS58148814A (ja) 1982-03-01 1983-09-05 Fujimoto Seiyaku Kk 消化酵素軟カプセル剤
JPS58179492A (ja) 1982-04-12 1983-10-20 Dainichi Seika Kogyo Kk 洗剤用酵素粒剤およびその製造方法
JPS59169491A (ja) 1983-03-15 1984-09-25 Duskin Franchise Co Ltd 酵素の安定化法
IE55711B1 (en) 1983-10-24 1990-12-19 Bausch & Lomb Improved method for enzymatic cleaning and disinfecting contact lenses
JPS61162185A (ja) 1985-01-09 1986-07-22 Nagase Seikagaku Kogyo Kk 顆粒状酵素製剤の製造方法
US4707287A (en) 1985-06-28 1987-11-17 The Procter & Gamble Company Dry bleach stable enzyme composition
JPH0622461B2 (ja) 1985-07-31 1994-03-30 キユーピー株式会社 水中油型乳化食品の製造方法
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
JPS63503390A (ja) 1986-05-21 1988-12-08 ノボ　インダストリ　アクテイ−ゼルスカブ 被覆された洗剤用酵素製品
DE3642853A1 (de) 1986-12-16 1988-06-23 Ulrich Von Dr Ing Pidoll Arzneimittel
DK435587D0 (da) 1987-08-21 1987-08-21 Novo Industri As Fremgangsmaade til fremstilling af et enzymholdigt granulat
DK435687D0 (da) 1987-08-21 1987-08-21 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
EP0305216B1 (en) 1987-08-28 1995-08-02 Novo Nordisk A/S Recombinant Humicola lipase and process for the production of recombinant humicola lipases
WO1989008694A1 (en) 1988-03-14 1989-09-21 Novo-Nordisk A/S Granulate detergent enzyme product, method for production thereof, use thereof, and detergent containing such product
DK78189D0 (da) 1989-02-20 1989-02-20 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
DK78089D0 (da) 1989-02-20 1989-02-20 Novo Industri As Detergentholdigt granulat og fremgangsmaade til fremstilling deraf
GB8915658D0 (en) 1989-07-07 1989-08-23 Unilever Plc Enzymes,their production and use
WO1991006638A1 (en) 1989-10-31 1991-05-16 Genencor International, Inc. Dust-free coated enzyme formulation
CA2030581C (en) 1989-11-24 2000-06-27 Gunther Atzl Pancreatin preparations
WO1991016060A1 (en) 1990-04-16 1991-10-31 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
JP3110437B2 (ja) 1990-05-17 2000-11-20 財団法人化学及血清療法研究所 流行性非ａ非ｂ型肝炎ウイルス抗原ペプチドおよびこれをコードする核酸断片
SG70966A1 (en) 1990-08-03 2000-03-21 Vertex Pharma Use of crosslinked crystals as a novel form of enzyme immobilization
JP3055799B2 (ja) 1990-11-21 2000-06-26 塩野義製薬株式会社 パンクレアチン含有組成物
US5254283A (en) 1991-01-17 1993-10-19 Genencor International, Inc. Isophthalic polymer coated particles
DK13491D0 (da) 1991-01-25 1991-01-25 Novo Nordisk As Anvendelse af et enzymholdigt granulat og fremgangsmaade til fremstilling af et forderstof i tabletform
DE4203315A1 (de) 1991-02-14 1992-08-20 Kali Chemie Pharma Gmbh Verfahren zur gewinnung von pankreatin
DK0610321T3 (da) 1991-10-07 2002-04-08 Genencor Int Granule indeholdende coatet enzym
WO1993007260A1 (en) 1991-10-10 1993-04-15 Genencor International, Inc. Process for dust-free enzyme manufacture
DE4200002A1 (de) 1992-01-02 1993-07-08 Rudolf V Dipl Chem Dr Noronha Reinigungstablette fuer die zahnprothesen
US5686238A (en) 1992-02-10 1997-11-11 Baxter International Inc. Method and device for testing blood units for viral contamination
ES2188593T3 (es) 1992-03-24 2003-07-01 United Cancer Res Inst Vacuna que contiene un virus vivo.
EP0671929A4 (en) 1992-10-16 1996-09-25 Smithkline Beecham Corp COMPOSITIONS.
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
CA2168870A1 (en) 1993-09-15 1995-03-23 Anthony Vincent Rawlings Skin care method and composition
FR2710535B1 (fr) 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE4422198C2 (de) 1994-06-24 1997-08-28 Audi Ag Verfahren zum Steuern der elektrischen Beheizung eines Katalysators
WO1996016151A1 (en) 1994-11-18 1996-05-30 Genencor International, Inc. Coated enzyme granules
JPH08143457A (ja) 1994-11-21 1996-06-04 Microbial Chem Res Found 酵素阻害剤および高脂血症抑制剤
US5851975A (en) 1995-05-29 1998-12-22 Kao Corporation Enzyme-containing granulated substance and preparation process thereof
JPH09125096A (ja) 1995-10-30 1997-05-13 Koei Sangyo:Kk 液状天然油脂洗剤
WO1997023605A1 (en) 1995-12-22 1997-07-03 Helix Biotechnology Ltd. Thermostable proteolytic enzyme from thermoactinomyces thalpophilus thm1
CN1135265C (zh) 1996-04-12 2004-01-21 诺沃奇梅兹有限公司 含酶颗粒及其生产方法
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
CA2198317C (en) 1997-02-24 2003-01-07 Mouhsine El Abboudi Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof
AUPO693397A0 (en) 1997-05-22 1997-06-12 Betatene Limited Carotenoid formulation
NZ330940A (en) 1997-07-24 2000-02-28 F Production of consensus phytases from fungal origin using computer programmes
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
KR100387245B1 (ko) 1997-10-17 2003-08-19 일양약품주식회사 유산균의안정화를위한미세장용성코팅과립
PL344534A1 (en) 1997-11-28 2001-11-05 Innogenetics Nv Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
KR19990072826A (ko) 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
US20030021844A1 (en) 1998-03-04 2003-01-30 Philippe Barthelemy Immediate-release oral pellet comprising polyglycolysed glycerides, and manufacturing process
FR2775597B1 (fr) 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
DE29824797U1 (de) 1998-05-22 2002-08-22 Bristol Myers Squibb Co Magensaftresistent überzogene Arzneimittel
ATE255158T1 (de) 1998-06-30 2003-12-15 Novozymes As Neues, verbessertes, enzym enthaltendes granulat
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz
DE19856415C2 (de) 1998-12-08 2001-06-07 Thomas Fenner Verfahren zur Reinigung bzw. Isolierung viraler Nukleinsäuren
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4790957B2 (ja) 1999-10-01 2011-10-12 ノボザイムス アクティーゼルスカブ 酵素粒質物
JP4731777B2 (ja) 1999-10-12 2011-07-27 マルホ株式会社 経口医薬組成物
MX261332B (es) 2000-02-08 2008-10-14 Hoffmann La Roche Uso de proteasas estables en acido para alimento de animales.
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
CN1336434A (zh) * 2000-08-01 2002-02-20 上海惠海生化制品厂 胰激肽原酶的制备及其亲和层析纯化方法
CN1452657A (zh) 2000-09-08 2003-10-29 诺和酶股份有限公司 润滑颗粒
JP2004510424A (ja) 2000-10-02 2004-04-08 ノボザイムス　アクティーゼルスカブ 活性物質を含有するコートされた粒子
ATE346590T1 (de) 2001-07-26 2006-12-15 Ethypharm Sa Umgehüllte allylamine oder benzylamine enthaltende granulate, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die umgehüllten granulate
US6783968B2 (en) * 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US20030191093A1 (en) 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2003055967A1 (en) 2001-12-21 2003-07-10 Novozymes A/S Salt coatings
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
EP1490485B1 (en) 2002-03-27 2015-03-04 Novozymes A/S Granules with filamentous coatings
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
US20060234340A1 (en) 2003-02-06 2006-10-19 Novozymes A/S Human heavy chain antibody expression in flamentous fungi
WO2005070962A1 (en) 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
EP1739070B1 (en) 2004-04-23 2013-12-04 Idemitsu Kosan Co., Ltd. Magnesium compound, catalyst for olefin polymerization and method for producing olefin polymer
ITMI20040891A1 (it) 2004-05-04 2004-08-04 Ibsa Inst Biochimique Sa Nuovo metodo per la partizione ed inattivazione di contaminanti virali e prionici
US7718169B2 (en) 2004-10-14 2010-05-18 Cystic Fibrosis Foundations Therapeutics, Inc. Compositions and methods for treating pancreatic insufficiency
RU2007149045A (ru) 2005-06-24 2009-07-10 Новозимс А/С (Dk) Липазы для фармацевтического применения
WO2007014896A1 (en) 2005-07-29 2007-02-08 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2007020260A2 (en) 2005-08-15 2007-02-22 Solvay Pharmaceuticals Gmbh Pancreatin micropellet cores suitable for enteric coating
SI1931316T2 (sl) 2005-08-15 2017-05-31 Abbott Laboratories Gmbh Farmacevtski sestavki z nadzorovanim sproščanjem za kislinsko labilna zdravila
CA2653127C (en) 2006-05-22 2015-09-15 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2455462B1 (en) 2006-12-21 2016-03-16 Novozymes A/S Lipase variants for pharmaceutical use
CA2677989C (en) 2007-02-20 2018-04-24 Eurand Pharmaceuticals Limited Stable digestive enzyme compositions

Patent Citations (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324002A (en) * 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
US3803305A (en) * 1962-12-28 1974-04-09 Rolland A Lab Process for obtaining extracts from pancreas
US3956483A (en) * 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
US3950508A (en) * 1972-05-10 1976-04-13 Laboratoires Servier Process for obtaining pharmaceutical sustained releases
US4019958A (en) * 1975-03-22 1977-04-26 Kali-Chemie Pharma Gmbh Continuous process of producing pancreatin and product thereof
US3986927A (en) * 1975-04-28 1976-10-19 Armour Pharmaceutical Company Process for the purification and sterilization of acidophilic biologicals by extreme acidification at cold temperatures
US4079125A (en) * 1975-06-10 1978-03-14 Johnson & Johnson Preparation of enteric coated digestive enzyme compositions
US4106991A (en) * 1976-07-07 1978-08-15 Novo Industri A/S Enzyme granulate composition and process for forming enzyme granulates
US4280971A (en) * 1979-06-08 1981-07-28 Kali-Chemie Pharma Gmbh Process for the production of pancreatin pellets
US4533562A (en) * 1981-04-13 1985-08-06 Sankyo Company, Limited Method of preparing coated solid preparations
US4623624A (en) * 1982-12-30 1986-11-18 Basf Aktiengesellschaft Isolation of pancreatin
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
US4689297A (en) * 1985-03-05 1987-08-25 Miles Laboratories, Inc. Dust free particulate enzyme formulation
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5863759A (en) * 1986-03-17 1999-01-26 Novo Nordisk A/S Process for the production of protein products in aspergillus
US5766912A (en) * 1986-03-17 1998-06-16 Novo Nordisk A/S Humicola lipase produced in aspergillus
US5874558A (en) * 1986-03-17 1999-02-23 Novo Nordisk Nucleic acid encoding a recombinant humicola sp. lipase
US4786505A (en) * 1986-04-30 1988-11-22 Aktiebolaget Hassle Pharmaceutical preparation for oral use
US5536661A (en) * 1987-03-10 1996-07-16 Novo Nordisk A/S Process for the production of protein products in aspergillus
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US4929774A (en) * 1988-01-29 1990-05-29 Basf Aktiengesellschaft Stable mixture containing oxidation-sensitive compounds, preparation thereof and use of a combination of substances for stabilizing oxidation-sensitive compounds
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5300433A (en) * 1989-06-15 1994-04-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
US5658871A (en) * 1989-07-07 1997-08-19 Lever Brothers Company, Division Of Conopco, Inc. Microbial lipase muteins and detergent compositions comprising same
US6187572B1 (en) * 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US5614189A (en) * 1990-06-06 1997-03-25 Novo Nordisk A/S Recombinantly produced lipases for therapeutical treatment
US6004768A (en) * 1990-08-03 1999-12-21 Vertex Pharmaceuticals, Inc. Biosensors, extracorporeal devices and methods for detecting substances using crosslinked protein crystals
US5801022A (en) * 1990-08-03 1998-09-01 Vertex Pharmaceuticals, Incorporated Method of producing a product with crosslinked crystals of thermolysin
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US6011001A (en) * 1990-08-03 2000-01-04 Vertex Pharmaceuticals, Inc. Method of protein therapy by orally administering crosslinked protein crystals
US5976529A (en) * 1990-08-03 1999-11-02 Vertex Pharmaceuticals, Inc. Methods of enzyme therapy by orally administering crosslinked enzyme crystals
US5849296A (en) * 1990-08-03 1998-12-15 Vertex Pharmaceuticals, Inc. Crosslinked protein crystals
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
US5374657A (en) * 1991-01-24 1994-12-20 Martek Corporation Microbial oil mixtures and uses thereof
US5489530A (en) * 1991-07-01 1996-02-06 Basf Aktiengesellschaft Lipase from Pseudomonas and strain
US5645832A (en) * 1991-07-01 1997-07-08 Basf Aktiengesellschaft Use of lipases for producing drugs
US6030798A (en) * 1991-07-01 2000-02-29 Basf Aktiengesellschaft Method of identifying a lipase for treatment of digestive disorders
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5324649A (en) * 1991-10-07 1994-06-28 Genencor International, Inc. Enzyme-containing granules coated with hydrolyzed polyvinyl alcohol or copolymer thereof
US5879920A (en) * 1991-10-07 1999-03-09 Genencor International, Inc. Coated enzyme-containing granule
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5378462A (en) * 1992-08-19 1995-01-03 Kali-Chemie Pharma Gmbh Pancreatin micropellets prepared with polyethylene glycol 4000, paraffin and a lower alcohol by extrusion and rounding
US5570104A (en) * 1993-02-24 1996-10-29 Sony Corporation Discharge chamber and method of manufacturing the same
US5719115A (en) * 1993-07-05 1998-02-17 Henkel Kommanditgesellschaft Auf Aktien Coated enzyme preparation for detergents and cleaning formulations
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5783545A (en) * 1993-12-23 1998-07-21 Henkel Kommanditgesellschaft Auf Aktien Enzyme preparation containing a silver corrosion inhibitor
US5725880A (en) * 1994-03-11 1998-03-10 Tanabe Seiyaku Co., Ltd. Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract
US5750148A (en) * 1994-08-19 1998-05-12 Shin-Etsu Chemical Co., Ltd. Method for preparing solid enteric pharmaceutical preparation
US6051220A (en) * 1995-05-31 2000-04-18 Medzyme N.V. And Simon Lodewijk Scharpe Composition to improve digestibility and utilization of nutrients
US6025391A (en) * 1996-04-12 2000-02-15 Novartis Ag Enteric-coated pharmaceutical compositions of mycophenolate
US6355461B2 (en) * 1996-04-29 2002-03-12 Novozymes A/S Non-aqueous, liquid, enzyme-containing compositions
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5993806A (en) * 1996-08-28 1999-11-30 Solvay Pharmaceuticals Gmbh Method of stabilizing pharmaceutical preparations comprising digestive enzyme mixtures
US6278794B1 (en) * 1996-11-29 2001-08-21 Oxford Glycosciences (Uk) Ltd Computer-assisted isolation and characterization of proteins
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US20030211127A1 (en) * 1997-04-11 2003-11-13 Margolin Alexey L. Controlled dissolution crosslinked prote in crystals
US20040202643A1 (en) * 1997-04-11 2004-10-14 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US20020137156A1 (en) * 1997-04-11 2002-09-26 Alexey L. Margolin Controlled dissolution crosslinked protein crystals
US6426091B1 (en) * 1997-09-30 2002-07-30 Nikken Chemicals Co., Ltd. Sustained-release theophylline tablet
US20030175259A1 (en) * 1998-03-09 2003-09-18 Hamper Karageozian Use of corneal hardening agents in enzymeorthokeratology
US20020076438A1 (en) * 1998-05-22 2002-06-20 Ismat Ullah High drug load acid labile pharmaceutical composition
US6224910B1 (en) * 1998-05-22 2001-05-01 Bristol-Myers Squibb Company Method for the preparation of an enteric coated high drug load pharmaceutical composition
US6348442B2 (en) * 1998-06-30 2002-02-19 Novozymes A/S Enzyme containing granule
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US20020061302A1 (en) * 1999-03-17 2002-05-23 Suntje Sander-Struckmeier Method for the treatment of diabetes
US6767729B1 (en) * 1999-05-27 2004-07-27 Amano Enzyme Inc. Enzyme liquor and process for producing the same enzyme preparation protease preparations and protease-producing bacterium
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6734188B1 (en) * 1999-11-01 2004-05-11 John Rhodes Composition for treatment of constipation and irritable bowel syndrome
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7211281B2 (en) * 1999-12-30 2007-05-01 Kemin Industries, Inc. Method for improving the activity of enzymes
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20030017144A1 (en) * 2000-02-24 2003-01-23 Altus Biologics Inc. Lipase-containing composition and methods of use thereof
US20040013697A1 (en) * 2000-05-30 2004-01-22 Gunther Berndl Self-emulsifying active substance formulation and use of this formulation
US20020146451A1 (en) * 2000-07-15 2002-10-10 Sharma Virender K. Method for the administration of acid-labile drugs
US20040033220A1 (en) * 2000-11-02 2004-02-19 Marcus Hartmann Use of enzymes obtained from ciliates as medicaments for promoting digestion
US20080292610A1 (en) * 2000-11-02 2008-11-27 Cilian Ag Medicaments containing enzymes from ciliates for promoting digestion in digestive disorders
US20040101562A1 (en) * 2000-11-15 2004-05-27 Mario Maio Microspheres of pancreatic enzymes with high stability and production method thereof
US20040057944A1 (en) * 2001-01-19 2004-03-25 Solvay Pharmaceuticals Gmbh Microbial enzyme mixtures useful to treat digestive disorders
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US20030007962A1 (en) * 2001-05-23 2003-01-09 Vergez Juan A. Pharmaceutical composition containing mosapride and pancreatin
US20030086948A1 (en) * 2001-07-27 2003-05-08 Gattefosse S.A. Pharmaceutical composition for oral use comprising an active principle to undergo a large first intestinal passage effect
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
US20030049245A1 (en) * 2001-08-31 2003-03-13 Mann David M. Methods for sterilizing preparations of digestive enzymes
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
US7479378B2 (en) * 2003-07-29 2009-01-20 Solvay Pharmaceuticals Gmbh Method of analyzing enzyme compositions with lipolytic, proteolytic and amylolytic activity
US20050250817A1 (en) * 2004-03-22 2005-11-10 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US20070148153A1 (en) * 2005-08-15 2007-06-28 George Shlieout Controlled release pharmaceutical compositions for acid-labile drugs
US20070148152A1 (en) * 2005-08-15 2007-06-28 George Shlieout Process for the manufacture and use of pancreatin micropellet cores
US20080019959A1 (en) * 2006-05-22 2008-01-24 Dietmar Becher Process for separating and determining the viral load in a pancreatin sample
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090226414A1 (en) * 2008-03-07 2009-09-10 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations

Cited By (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071683A1 (en) * 1999-12-17 2004-04-15 Fallon Joan M. Methods for treating pervasive development disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US8613918B2 (en) 1999-12-17 2013-12-24 Curemark Llc Method for treating pervasive development disorders
US8211661B2 (en) 1999-12-17 2012-07-03 Curemark, Llc Method for identifying individuals having a pervasive development disorder amenable to digestive enzyme therapy
US8163278B2 (en) 1999-12-17 2012-04-24 Curemark Llc Methods for treating pervasive development disorders
US9624526B2 (en) 1999-12-17 2017-04-18 Curemark Llc Method for treating pervasive development disorders
US9624525B2 (en) 1999-12-17 2017-04-18 Curemark, Llc Method for treating pervasive development disorders
US20090286270A1 (en) * 1999-12-17 2009-11-19 Fallon Joan M Method for treating pervasive development disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US20080152637A1 (en) * 2000-08-14 2008-06-26 Fallon Joan M Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders
US9884025B2 (en) 2000-11-15 2018-02-06 Aptalis Pharma S.R.L. Microspheres of pancreatic enzymes with high stability and production method thereof
US9259393B2 (en) 2000-11-15 2016-02-16 Aptalis Pharma S.R.L. Microspheres of pancreatic enzymes with high stability and production method thereof
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US9377459B2 (en) 2000-11-16 2016-06-28 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US10209253B2 (en) 2000-11-16 2019-02-19 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20070270976A1 (en) * 2002-04-25 2007-11-22 Ultraflex Systems, Inc. Ambulating ankle & knee joints with bidirectional dampening and assistance using elastomeric restraint
US8802087B2 (en) 2004-03-22 2014-08-12 Abbott Products Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US20050250817A1 (en) * 2004-03-22 2005-11-10 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US20080166334A1 (en) * 2004-09-28 2008-07-10 Fallon Joan M Combination enzyme for cystic fibrosis
US20100233218A1 (en) * 2004-09-28 2010-09-16 Curemark Llc Combination enzyme for cystic fibrosis
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20070148152A1 (en) * 2005-08-15 2007-06-28 George Shlieout Process for the manufacture and use of pancreatin micropellet cores
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20070148153A1 (en) * 2005-08-15 2007-06-28 George Shlieout Controlled release pharmaceutical compositions for acid-labile drugs
US11033563B2 (en) 2005-08-30 2021-06-15 Curemark, Llc Use of lactulose in the treatment of autism
US10350229B2 (en) 2005-08-30 2019-07-16 Curemark, Llc Use of lactulose in the treatment of autism
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20080019959A1 (en) * 2006-05-22 2008-01-24 Dietmar Becher Process for separating and determining the viral load in a pancreatin sample
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US10206882B2 (en) 2007-02-20 2019-02-19 Allergan Pharmaceuticals International Limited Stable digestive enzyme compositions
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US10087493B2 (en) * 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US20090226414A1 (en) * 2008-03-07 2009-09-10 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US20090233344A1 (en) * 2008-03-11 2009-09-17 Nordmark Arzneimittel Gmbh & Co. Kg Pancreatin and method for reducing the viral and microbial contamination of pancreatin
US8283147B2 (en) 2008-03-11 2012-10-09 Nordmark Arzneimittel Gmbh & Co. Kg Pancreatin and method for reducing the viral and microbial contamination of pancreatin
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9925250B2 (en) 2008-03-13 2018-03-27 Curemark, Llc Method of treating proteinuria in pregnancy
US20090232789A1 (en) * 2008-03-13 2009-09-17 Fallon Joan M Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy
US9408895B2 (en) 2008-03-13 2016-08-09 Curemark, Llc Method of treating pregnancy-induced hypertension
US11045527B2 (en) 2008-03-13 2021-06-29 Curemark, Llc Method of diagnosing preeclampsia or pregnancy-induced hypertension
US10272141B2 (en) 2008-04-18 2019-04-30 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8486390B2 (en) 2008-04-18 2013-07-16 Curemark Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8318158B2 (en) 2008-04-18 2012-11-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US11235038B2 (en) 2008-04-18 2022-02-01 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9687534B2 (en) 2008-04-18 2017-06-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US10588948B2 (en) 2008-06-26 2020-03-17 Curemark, Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US20090324572A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of williams syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US20110182818A1 (en) * 2008-07-01 2011-07-28 Fallon Joan M Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US20100169409A1 (en) * 2008-08-04 2010-07-01 Fallon Joan M Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
US9687535B2 (en) 2008-10-03 2017-06-27 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US10413601B2 (en) 2008-10-03 2019-09-17 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
DE202008014562U1 (de) 2008-11-03 2009-02-26 Nordmark Arzneimittel Gmbh & Co. Kg Pankreatin
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US10736946B2 (en) 2009-01-06 2020-08-11 Galenagen, Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9895427B2 (en) 2009-01-06 2018-02-20 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US11357835B2 (en) 2009-01-06 2022-06-14 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US20100260857A1 (en) * 2009-04-13 2010-10-14 Joan Fallon Enzyme delivery systems and methods of preparation and use
US9931302B2 (en) 2009-04-13 2018-04-03 Curemark , LLC Enzyme delivery systems and methods of preparation and use
US11419821B2 (en) 2009-04-13 2022-08-23 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US10098844B2 (en) 2009-04-13 2018-10-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9415014B2 (en) 2009-04-13 2016-08-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
WO2011035079A1 (en) 2009-09-17 2011-03-24 Eurand, Inc. Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US10716835B2 (en) 2009-10-21 2020-07-21 Curemark, Llc Methods and compositions for the prevention and treatment of influenza
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US11364205B2 (en) 2010-10-01 2022-06-21 Societe Des Produits Nestle S.A. Stable low digestive enzyme content formulation
US10940187B2 (en) 2011-04-21 2021-03-09 Curemark, Llc Method of treatment of schizophreniform disorder
US9492515B2 (en) 2011-04-21 2016-11-15 Curemark, Llc Method of treatment of schizophreniform disorder
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US10279016B2 (en) 2011-04-21 2019-05-07 Curemark, Llc Method of treatment of schizophreniform disorder
US9976171B2 (en) 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11364287B2 (en) 2012-05-30 2022-06-21 Curemark, Llc Methods of treating celiac disease
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Also Published As

Publication number Publication date
RU2413532C2 (ru) 2011-03-10
EP1913138A1 (en) 2008-04-23
HUE031042T2 (en) 2017-06-28
ES2597381T3 (es) 2017-01-18
AU2006274835B2 (en) 2012-05-24
BRPI0614914A2 (pt) 2011-04-19
US20200299669A1 (en) 2020-09-24
EP2278002B1 (en) 2017-07-12
KR20080036622A (ko) 2008-04-28
EP1913138B1 (en) 2016-08-24
PL1913138T3 (pl) 2017-07-31
AU2006274835A1 (en) 2007-02-08
HUE034739T2 (en) 2018-02-28
HK1120288A1 (en) 2009-03-27
NO20171131A1 (no) 2008-04-28
US10704037B2 (en) 2020-07-07
IL189103A (en) 2012-03-29
PL2278002T3 (pl) 2017-12-29
CN101233229A (zh) 2008-07-30
NO342419B1 (no) 2018-05-22
US20170073660A1 (en) 2017-03-16
NO20081087L (no) 2008-04-28
KR101555058B1 (ko) 2015-09-22
ES2635308T3 (es) 2017-10-03
EP2278002A1 (en) 2011-01-26
IL189103A0 (en) 2008-08-07
MX2008000850A (es) 2008-03-18
CA2616943C (en) 2016-04-12
NO340996B1 (no) 2017-07-31
UA93384C2 (ru) 2011-02-10
WO2007014896A1 (en) 2007-02-08
JP5140586B2 (ja) 2013-02-06
CA2616943A1 (en) 2007-02-08
JP2009502876A (ja) 2009-01-29
CN101233229B (zh) 2013-05-01
RU2008107261A (ru) 2009-09-10

Similar Documents

Publication Publication Date Title
US20200299669A1 (en) Processes for the Manufacture and Use of Pancreatin
ES2385958T3 (es) Procedimiento para reducir la carga viral y microbiana de pancreatina
TR201808840T4 (tr) Stabil sindirim enzimi bileşimleri.
AU2015275860A1 (en) Methods for removing viral contaminants from pancreatic extracts
EP3436055B1 (en) Enzyme compositions with reduced viral and microbial contamination
US9107966B2 (en) Method for reducing the viral and microbial load of biological extracts containing solids
US20220211825A1 (en) Enzyme compositions with reduced viral and microbial contamination
CN111630164A (zh) 具有减少的病毒和微生物污染的酶组合物
Wang et al. The H protein of attenuated canine distemper virus is degraded via endoplasmic reticulum-associated protein degradation
EA045569B1 (ru) Ферментный препарат со сниженным уровнем вирусного и микробного загрязнения и способ его получения
EA045327B1 (ru) Композиции ферментов с уменьшенным вирусным и микробным загрязнением
EA040925B1 (ru) Препарат панкреатина с уменьшенной вирусной и микробной нагрузкой и способ его получения

Legal Events

Date Code Title Description
AS Assignment

Owner name: SOLVAY PHARMACEUTICALS GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRINK, MARTIN;KOELLN, CLAUS-JUERGEN;BLUME, HEINZ;AND OTHERS;REEL/FRAME:018954/0313;SIGNING DATES FROM 20070206 TO 20070215

AS Assignment

Owner name: ABBOTT PRODUCTS GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:SOLVAY PHARMACEUTICALS GMBH;REEL/FRAME:027408/0558

Effective date: 20100325

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION